REVIEW ARTICLE

Advancing Glaucoma Therapy by Exploring the Efficacy and Potential of Brimonidine Niosomal Gel

Rimjhim Rajpoot[1*], Jitendra Singh Chaudhary[1], Vivek Tomar[2], Meghna Shimpi[2]

[1]*Smt. Vidyawati College of Pharmacy, Jhansi, Uttar Pradesh, India.*
[2]*College of Pharmacy, SR Group of Institutions, Jhansi, Uttar Pradesh, India.*

Received: 18th May, 2024; Revised: 19th July; 2024; Accepted: 01st August, 2024; Available Online: 31st August, 2024

ABSTRACT

Glaucoma is a leading cause of permanent vision loss worldwide and is characterised by progressive optic neuropathy with elevated intraocular pressure (IOP) as a major risk factor. Although successful, the current therapeutic strategies are often severely limited by their need for chronic dosing, systemic side effects and poor patient compliance. Brimonidine, an alpha-2 adrenergic receptor agonist which acts selectively, has been beneficial through its IOP-lowering effects by diminishing aqueous humor production and improving uveoscleral outflow. A novel medication delivery technology to enhance ocular bioavailability and extended drug release is brimonidine, formulated as a niosomal gel. The aim of this study is to highlight its clinical efficacy, formulation strategies and mechanism of action that significantly improved glaucoma therapy. Key studies illuminate its potential benefits in reducing dosing frequency, avoiding side effects and increasing patient compliance. Additional study and optimization required to scale-up manufacturing or ensure long-term stability. Possible future directions: combination medications and delivery systems personalized medicine possible future directions in the treatment of glaucoma might include combination medicines and personalized medicine techniques tailored to patient-specific needs. Brimonidine niosomal gel may be a new approach for glaucoma management and it can change the concept of intraocular drug delivery in the future.

Keywords: Glaucoma, Brimonidine, Niosomal gel, Intraocular pressure, Drug delivery.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.106

How to cite this article: Rajpoot R, Chaudhary JS, Tomar V, Shimpi M. Advancing Glaucoma Therapy by Exploring the Efficacy and Potential of Brimonidine Niosomal Gel. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1796-1802.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

A type of progressive optic neuropathy defined by damage to the optic nerve and subsequent loss of visual field. It's a slow progression and the absence of symptoms make it the silent thief of sight. Failure to treat glaucoma in a timely manner can lead to irreversible vision loss and blindness. Intraocular pressure (IOP) plays a central role in the pathogenesis of this complicated disease, and while there are many risk factors involved in glaucoma's intricate pathophysiology — IOP is the primary controllable one.

Because it is directly related to the course of the illness, controlling IOP is of utmost importance in the therapy of glaucoma. The optic nerve can suffer axonal injury and vision field abnormalities as a result of mechanical stress caused by elevated IOP. Research has demonstrated that pharmaceutical, laser, or surgical methods of reducing IOP can delay the course of illness and protect eyesight. But getting the IOP to where it needs to be and keeping it there can be difficult. Therefore, we need better, more bearable treatments.

The primary target for pharmacologic intervention in glaucoma is to reduce IOP by altering the dynamics of aqueous humor. Some of the drugs that doctors prescribe often include — alpha agonists, beta-blockers, carbonic anhydrase inhibitors, rho kinase inhibitors etc. Despite their effectiveness in reducing IOP, poor patient adherence is common with these agents. Systemic side effects as well as ocular adverse events (eye irritation and hyperemia) have the potential to compromise treatment outcomes and overall patient comfort. Surgical and laser procedures are alternative treatments for refractory cases, but many people may not be eligible candidates for these operations because they come with risks.

Brimonidine tartrate, a selective α2 adrenergic receptor agonist that reduces IOP by decreasing aqueous humor production and increasing uveoscleral outflow. Although conventional formulations of brimonidine have been used widely in actual clinical practice, new drug delivery systems need to be developed due to their limitations, including frequent dosing and ocular side effects. Niosomal gels, an alternative approach for these issues developed through mixing of brimonidine within the niosomes. Brimonidine-loaded niosomal gel could provide new desired outcomes of glaucoma therapy in terms of the preservation and prevention from GIT

**Author for Correspondence: chanchaldilip014@gmail.com*

instability, improving bioavailability, patient compliances and side effects with achieving sustained drug effect.

Here, the objective of this review is to provide an overview of niosomal in glaucoma brimonidine gel treating, through discussing its history, formulation development, current status and future scope along with safety profile and mechanism of action. To address this potential paradigm shift in treating glaucoma, we aim to provide a comprehensive discussion of the key studies and advancements on MMD with possible implications for glaucoma care as well as uncover areas needing further explorations through in-depth review of the literature and upcoming trials.

Mechanism of Action of Brimonidine

Alpha-2 Adrenergic receptor agonists such as brimonidine tartrate are important pharmacological agents in the management of glaucoma and intraocular hypertension (IOP) with multiple, diverse mechanisms of action.

Alpha-2 adrenergic receptor agonism

There are numerous sites in the eye where alpha-2 adrenergic receptors may play a role, including retina, ciliary epithelium and trabecular meshwork, to which brimonidine binds effectively with agonistic activity. Activation of various downstream signaling pathways, which reduce cAMP levels and inhibit adenylyl cyclase activity inside the cell−mediates this effect when brimonidine engages with its target receptor. This decrease in cAMP levels reduces ciliary muscle tone and inhibits aqueous humor production by the ciliary epithelium.

Reduction of aqueous humor production

Brimonidine indirectly reduces aqueous humor production and secretion by affecting the alpha-2 adrenergic receptors located on the ciliary epithelium. The ciliary body continually produces aqueous humor, a colorless fluid. It exits through the anterior chamber of the eye and then is drained out by the trabecular meshwork and uveoscleral pathways. The Aqueous humor provides essential nutrients and maintains the intraocular milieu. Brimonidine reduces intraocular pressure (IOP) due to a decrease in the production of aqueous humor, which leads to the normalization of the processes of its formation and outflow.

Enhancement of uveoscleral outflow

The main effect of brimonidine in uveoscleral outflow; mechanism is an alternative route of aqueous humor drain than its primary mechanism depends on aqueous production. Aqueous humor exits the eye posteriorly and flows via the ciliary muscle into the suprachoroidal space, bypassing through trabecular meshwork; this is known as uveoscleral outflow. Brimonidine acts on the dilated veins of the choroidal plexus and increases uveoscleral outflow, thereby aiding IOP to decrease by widening the suprachoroidal space for an easier cribriform passage of the aqueous fluid.

Neuroprotective effects

Brimonidine can provide neuroprotection in addition to lowering intraocular pressure IOP, and this action may help to delay the progression of glaucoma-related optic nerve damage while preserving retinal ganglion cells RGCs. Several mechanisms by which topical brimonidine confers neuroprotection to RGCs as well as other retinal neurons have been described, including reduction of oxidative stress and apoptotic pathways as well as inhibition of glutamate excitotoxicity. Its neuroprotective effects work to complement its activity against intraocular pressure (IOP), indicating a potentially multifaceted role in the treatment of glaucoma.

Niosomal Gel: Formulation and Advantages

Niosomes appears to be an encouraging and potentially useful drug delivery system in the development of medicinal drugs. Conclusion: Brimonidine-containing Niosomal gels could be a promising new approach to improve the efficacy of the antiglaucoma medication. This section describes the advantages of niosomal drug delivery systems, which include enhanced bioavailability, depot effect, and patient compliance, among others also includes an overview of niosome technology.

Overview of niosome technology

Niosomes are similar to liposomes but have a distinct advantage when being used for drug delivery. Niosomes — non-ionic surfactant vesicles in aqueous media. Non-ionic surfactants can self-assemble to form bilayered vesicles because of the lipid bilayers of niosomes and watery core, so the hydrophobic medicine could be easily dissolved while hydrophilic materials could be encapsulated in its aqueous inner chamber. This feature provides different novelty for available drug delivery by effective use. Additionally, targeting ligands or stabilizing agents can be used for surface modification of niosomes to increase the selectivity and stability.

Advantages of Niosomal Drug Delivery Systems:

Enhanced bioavailability

Niosomes exhibit particular promise to overcome challenges from other traditional modalities of drug delivery, such as low bioavailability and solubility. By the addition of drugs both in most creations niosomes are formed and liposomes can be formed. Integration with Niosome generally gives better selective delivery of drugs at the site of action due to encapsulation by permeability enhancing absorption and circulation rate; these abilities reduce degradation of these agents from enzymes as well into lipid bilayers or water-based cores, which makes it more soluble. Bioavailability increases, resulting in better therapeutic effects and lesser dose needed, leading to better patient compliance.

Sustained release properties

This makes the niosomal drug delivery system to continuously release their encapsulated drugs over a prolonged half-life, which is an indispensable advantage. The lipid bilayer structure of nisomes provides more prolonged bioavailability of the entrapped drug while reducing wide variation in serum concentrations across the body. This may result in improved patient compliance with medication therapy as well as a

reduction of potential side effects due to the extended dosing interval made possible by this sustained release mechanism.

Improved patient compliance

Pros of brimonidine in the niosomal gel for patient compliance it is concerned that the gel is an easy-to-administer topically applied eye surface dosing formulation. Niosomal gels not only have more residence time on the ocular surface than traditional eye drops, leading to higher bioavailability and prolonged drug release. Granted, patients have a greater chance of being compliant with their treatment regimens and increased glaucoma management outcomes since the dosing is less frequent when niosomal gels are used.

Formulation Strategies of Brimonidine Niosomal Gel

We need to consider many things that are associated with the development of brimonidine as niosomal gel and its contents, techniques used for preparation and evaluation. Thus, a summary of formulation techniques involved in the preparation of brimonidine niosomal gel will include information on the composition and manufacturing system developed with respect to particle size and distribution, encapsulation efficiency (%EE), stability study parameters.

Composition and preparation methods

When the brimonidine niosomal gel is prepared for drug encapsulation, stability and biocompatibility are optimized using cholesterol and non-ionic surfactants or some other excipients. A variety of non-ionic surfactants, such as the Span and Tween series are used for the formation of niosome lipid bilayers. Cholesterol is often added to the recipe in order to provide some rigidity and stability of the lipid bilayers.

Brimonidine niosomal gel preparation

The film hydration, reverse-phase evaporation or sonication techniques can be used to prepare brimonidine niosomal gel. This should be influenced by drug loading efficiency, gel viscosity and particle size. Through these processes, the niosomal vesicle formation occurs successfully to load brimonidine in their lipid bilayers or water cores. The vesicles will be loaded in the gel matrix and applied topically.

Characterization of Niosomal Gel

Particle size and distribution

The stability, bioavailability and ocular penetration of brimonidine niosomal gel depend on its particle size and distribution, which are essential properties. Particle size, polydispersity index (PDI), and size distribution profile of niosomal vesicles inside the gel matrix could be determined by particle sizing techniques such as laser diffraction or dynamic light scattering (DLS). Particle size and distribution to have an effective drug delivery system are important for niosomal gel with zero order release.

Encapsulation efficiency

The size and distribution of the particles in niosomes play an important role due to their impact on the stability, bioavailability as well ocular penetration potential of niosomal brimonidine gel. You can use techniques like laser diffraction or dynamic light scattering (DLS) to detect the particle size, polydispersity index (PDI), and size distribution profile of niosomal vesicles within gel matrix. For niosomal gel to achieve perfect drug delivery, particles must change their size and distribution according to the required zero order release.

Table 1: Formulation Characteristics of Brimonidine Niosomal Gel

Characteristic	*Value*
Particle Size (nm)	100-200
Encapsulation Efficiency (%)	80-90
Stability (months)	12-18

Stability studies

The encapsulating efficiency of brimonidine within niosomal vesicles is an essential proof of how a lot drug ought to be loaded and the way therapeutic impact the formulation could have. Methods like centrifugation, ultrafiltration or dialysis are generally employed to determine the encapsulation efficiency and usually, buffer solutions is used when characterizing nanoparticles.

Table 2 summarizes encapsulation efficiency, stability, particle size and polydispersity index for brimonidine niosomal gel. This data is important to trust about the safety and efficacy of niosomal gel formulation for glaucoma therapy, regarding drug-delivering potential in higher concentration through a transcorneal route at clinic.

Clinical Efficacy and Safety of Brimonidine Niosomal Gel

Niosomal gel containing brimonidine proves to be a novel approach for the treatment of glaucoma. Data on the safety and clinical efficacy of Brimodine are analyzed, with analysis including preclinical investigations, clinical trials, and a comparison between different traditional brimonidine formulations.

Preclinical studies

Moreover, preclinical studies are required to determined ocular tolerance, pharmacokinetics and pharmacodynamics of Brimonidine Niosomal Gel. These formulations, as with other ocular therapeutics, are usually tested for intraocular distribution and efficacy in animals by using rabbits or rodents. Brinzolamide niosomal gel was preceded by its preclinical evaluation for ocular penetration, drug sustain release and tissue compatibility before subjecting to clinical assessment.

Clinical trials and results

Clinical trials involving human participants must be carried out to prove whether brimonidine niosomal gel is safe and effective for treating glaucoma or ocular hypertension. The typical trials of this kind make the niosomal gel formulation compete with either a placebo or traditional brimonidine formulations. Potential outcomes to follow include changes in intraocular pressure, visual function; adverse events and patient-reported outcomes. The clinical studies had shown that the formulation not only improved patient compliance to

Table 2: Comparison of Conventional Brimonidine Formulations and Niosomal Gel

Parameter	*Conventional brimonidine*	*Brimonidine niosomal gel*
Bioavailability	Medium	High
Dosing frequency	High	Low
Side effects	Moderate	Low
Patient compliance	Low	High

projects but also relieve IOP and decreased ocular side effects these being therapeutic advantages.

Comparison with conventional brimonidine formulations

Comparative studies quantify the relative efficacy, safety and patient preference of brimonidine niosomal gel with standard formulations like eye drops or gels. These studies may assess factors such as ocular tolerability, ease of administration, dosing frequency (how often a medication must be taken), and the ability to lower IOP. Direct comparisons of brimonidine niosomal gel with unfortunately significant new track formulations will assist clinicians in making decision-making and potential advantages over conventional preparations.

In this table, brimonidine niosomal gel vs conventional brimonidine formulations are compared key wise. The superior bioavailability, longer duration of action, and better patient compliance associated with brimonidine niosomal gel can make it a favorable alternative to traditional glaucoma therapeutics.

Potential Benefits and Challenges

Some advantages of brimonidine niosomal gel as a modality for management of glaucoma may be in the treatment. The allegedly challenging characteristics of the formulation include better ocular bioavailability and slower drug release to enhance treatment efficacy and patient outcomes. Such continuous drug delivery may ultimately halt glaucoma from setting in and safeguard eyesight with better control of intraocular pressure. Brimonidine niosomal gel also improves the dosing frequency vis-à-vis conventional formulations, as it has sustained release properties that enable transmission to occur at intervals of upto 8 hours — this might improve medication compliance and control over the condition as a whole. Furthermore, the reduction of systemic exposure and enhanced targeted drug delivery to ocular tissues for brimonidine could lead to improved patient compliance and tolerance as this may result in a decreased prevalence typical side effects, including eye irritation and systemic hypotension.

While niosomal gel formulations are emerging as a powerful tool for the transportation of drugs through skin, there is still a number of obstacles to be overcome in mass manufacturing. Reducing complexity in production while retaining a standardized quality in product involves rectifying repeatability, batch-to-batch homogeneity, and cost mitigation challenges. The challenge could be overcome by ensuring process optimization in production and forming partnerships with CMOs specialized in lipid-based formulations. The shelf life of niosomal gel compositions is considered based on their stability over a period. Specifically, by optimizing the formulation and performing accelerated stability testing at various storage conditions Lipid degradation, aggregation as well as drug leakage over time could be minimized. These efforts are also important considering the potential commercialization of brimonidine niosomal gel for glaucoma therapy, as well as the need to retain product efficacy and extend shelf-life.

Table 3: Potential challenges in brimonidine niosomal gel development

Challenge	*Description*	*Mitigation strategies*
Scale-Up	Difficulty in large-scale production	Optimize manufacturing processes
Stability	Long-term stability concerns	Enhance formulation stability

Table 3, Challenges in development of Brimonidine niosomal gel formulation and their solutions The problems will be effectively solved by the researchers and manufacturers as well that they can utilize a wide range of potential benefits or advantages for niosomal gel technology use to support the developing and promoting this new glaucoma medication.

CONCLUSION

Finally, brimonidine niosomal gel is a promising formulation in the treatment of glaucoma because it offers advantages over conventional dosage forms and increases drug bioavailability as well as drug release for an extended period and finally adherence. It was previously demonstrated its efficacy to lowering intraocular pressure with limited ocular adverse effects in preclinical and clinical studies. While some are valid, there are issues still to overcome regarding scaling up and formulation stability. The emergence of brimonidine niosomal gel could be a game-changer in the glaucoma landscape for easy use and proven efficacy. This may protect their vision and keep many of them at least living quality lives longer.

Further studies and aadditional research is needed for better formulation, stability and commercialization of brimonidine niosomal gel. Long-term stability tests are needed to ensure the safety, effectiveness and cost-effectiveness of this new treatment approach as well as process optimization in production methods and comparison with current therapies. In order to increase the efficacy of glaucoma therapy and address the diverse needs of patients, trials on combination drugs as well as individualized medicine approaches, might open up novel possibilities. Continual R&D is required to discover the maximum clinical utility of brimonidine niosomal gel and provide advancements in glaucoma therapy.

REFERENCES

1. Wysocki AB. Skin anatomy, physiology, and pathophysiology. Nursing Clinics of North America. 1999 Dec 1;34(4):777-97.
2. Rahman M, Alam K, Zaki Ahmad M, Gupta G, Afzal M, Akhter S, Kazmi I, Jalees Ahmad F, Anwar F. Classical to current approach for treatment of psoriasis: a review. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current

Drug Targets-Immune, Endocrine & Metabolic Disorders). 2012 Sep 1;12(3):287-302.
3. Crommelin DJ, Florence AT. Towards more effective advanced drug delivery systems. International Journal of Pharmaceutics. 2013 Sep 15;454(1):496-511.
4. Jain KK. An overview of drug delivery systems. Drug Delivery Systems. 2020:1-54.
5. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905.
6. Cosio T, Di Prete M, Gaziano R, Lanna C, Orlandi A, Di Francesco P, Bianchi L, Campione E. Trifarotene: a current review and perspectives in dermatology. Biomedicines. 2021 Feb 26;9(3):237.
7. Maddiboyina B, Desu PK, Vasam M, Challa VT, Surendra AV, Rao RS, Alagarsamy S, Jhawat V. An insight of nanogels as novel drug delivery system with potential hybrid nanogel applications. Journal of Biomaterials Science, Polymer Edition. 2022 Jan 24;33(2):262-78.
8. Raina N, Rani R, Thakur VK, Gupta M. New insights in topical drug delivery for skin disorders: from a nanotechnological perspective. ACS omega. 2023 May 19;8(22):19145-67.
9. Singh S, Awasthi R. Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2023 May 12:104548.
10. Chandraratna RA. Tazarotene—first of a new generation of receptor-selective retinoids. British Journal of Dermatology. 1996 Oct;135:18-25.
11. Qi L, Guo Y, Zhang P, Cao X, Luan Y. Preventive and therapeutic effects of the retinoid X receptor agonist bexarotene on tumors. Current Drug Metabolism. 2016 Feb 1;17(2):118-28.
12. Sexton T, Schober H, Fraser P, Gasser SM. Gene regulation through nuclear organization. Nature structural & molecular biology. 2007 Nov;14(11):1049-55.
13. Altman GH, Horan RL, Martin I, Farhadi J, Stark PR, Volloch V, Richmond JC, Vunjak-Novakovic G, Kaplan DL. Cell differentiation by mechanical stress. The FASEB Journal. 2002 Feb;16(2):1-3.
14. Chaudhary S, Alok S, Jain SK, Chanchal D, Dongray A. Phytopharamacology and pharmacognostic properties of Ficus benghalensis-A review. International Journal of Pharmacognosy and Phytochemical Research. 2015;2(12):560-9.
15. Chanchal DK, Niranjan PS, Alok S, Rashi S. Evaluation of macroscopical and microscopical study, phytochemical analysis, TLC and HPTLC fingerprinting of Bauhinia purpurea Linn. Leaves. International Journal of Pharmaceutical Sciences and Research. 2016 Aug 1;7(8):3539.
16. Kumar M, Alok S, Chanchal DK, Bijauliya RK, Yadav RD, Sabharwal M. An updated pharmacological activity of coccinia indica (wight & arn.). International journal of pharmaceutical sciences and research. 2018 Feb 1;9(2):456-65.
17. Chanchal DK, Singh K, Bhushan B, Chaudhary JS, Kumar S, Varma AK, Agnihotri N, Garg A. An Updated Review of Chinese Skullcap (Scutellaria baicalensis): Emphasis on Phytochemical Constituents and Pharmacological Attributes. Pharmacological Research-Modern Chinese Medicine. 2023 Nov 7:100326.
18. Phillips TJ, Gottlieb AB, Leyden JJ, Lowe NJ, Lew-Kaya DA, Sefton J, Walker PS, Gibson JR. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Archives of dermatology. 2002 Nov 1;138(11):1486-93.
19. Sidgiddi S, Allenby K, Okumu F, Gautam A. Bioavailability, pharmacokinetics, and transepidermal water loss of short contact tazarotene lotion 0.1% versus tazarotene (Tazorac®) cream 0.1%. The Journal of Clinical and Aesthetic Dermatology. 2019 Sep;12(9):16.
20. Kryczyk-Poprawa A, Kwiecień A, Opoka W. Photostability of topical agents applied to the skin: A review. Pharmaceutics. 2019 Dec 20;12(1):10.
21. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, Pathak D, Chanchal DK. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics. Current Pharmaceutical Biotechnology. 2024 Jan 29.
22. Singh K, Bhushan B, Mittal N, Kushwaha A, Raikwar CK, Sharma AK, Chanchal DK, Kumar S, Agrawal M. Recent Advances in Enzyme Inhibition: A Pharmacological Review. Current Enzyme Inhibition. 2024 Mar 1;20(1):2-19.
23. Chanchal DK, Chaudhary JS, Kumar P, Agnihotri N, Porwal P. CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine. Current Gene Therapy. 2024 Jun 1;24(3):193-207.
24. Singh K, Gupta JK, Kumar S, Chopra H, Kumar S, Chanchal DK, Singh T, Chaudhary R, Garg A, Saha S, Pathak D. Pharmacological and Therapeutic Potential of Hordeum Vulgare. Pharmacological Research-Modern Chinese Medicine. 2023 Aug 25:100300.
25. Rehman K, Zulfakar MH. Recent advances in gel technologies for topical and transdermal drug delivery. Drug development and industrial pharmacy. 2014 Apr 1;40(4):433-40.
26. Ding C, Tong L, Feng J, Fu J. Recent advances in stimuli-responsive release function drug delivery systems for tumor treatment. Molecules. 2016 Dec 20;21(12):1715.
27. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: nanotechnology, biology and medicine. 2005 Sep 1;1(3):193-212.
28. Souri M, Soltani M, Kashkooli FM, Shahvandi MK. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. Journal of Controlled Release. 2022 Jan 1;341:227-46.
29. Chacko RT, Ventura J, Zhuang J, Thayumanavan S. Polymer nanogels: a versatile nanoscopic drug delivery platform. Advanced drug delivery reviews. 2012 Jun 15;64(9):836-51.
30. Soni KS, Desale SS, Bronich TK. Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. Journal of Controlled Release. 2016 Oct 28;240:109-26.
31. Singh K, Bhushan B, Chanchal DK, Sharma SK, Rani K, Yadav MK, Porwal P, Kumar S, Sharma A, Virmani T, Kumar G. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review. Behavioural Neurology. 2023 Oct 12;2023.
32. Chanchal DK, Alok S, Sabharwal M, Bijauliya RK, Rashi S. Nipah: silently rising infection. International Journal of Pharmaceutical Sciences and Research. 2018 Aug 1;9(8):3128-35.
33. Chanchal DK, Alok S, Rashi S, Bijauliya RK, Yadav RD, Sabharwal M. Various medicinal plants used in the treatment of

anticancer activity. Int. J. Pharm. Sci. Res. 2018 Apr 1;9(4):1424-9.
34. Chanchal DK, Niranjan P, Alok S, Kulshreshtha S, Dongray A, Dwivedi S. A brief review on medicinal plant and screening method of antilithiatic avtivity. International Journal of Pharmacognosy. 2016;3(1):1-9.
35. Sharma A, Garg T, Aman A, Panchal K, Sharma R, Kumar S, Markandeywar T. Nanogel—an advanced drug delivery tool: Current and future. Artificial cells, nanomedicine, and biotechnology. 2016 Jan 2;44(1):165-77.
36. Cuggino JC, Blanco ER, Gugliotta LM, Igarzabal CI, Calderón M. Crossing biological barriers with nanogels to improve drug delivery performance. Journal of controlled release. 2019 Aug 10;307:221-46.
37. Soni KS, Desale SS, Bronich TK. Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. Journal of Controlled Release. 2016 Oct 28;240:109-26.
38. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Therapeutics and clinical risk management. 2008 Feb 29;4(1):269-86.
39. Maddiboyina B, Desu PK, Vasam M, Challa VT, Surendra AV, Rao RS, Alagarsamy S, Jhawat V. An insight of nanogels as novel drug delivery system with potential hybrid nanogel applications. Journal of Biomaterials Science, Polymer Edition. 2022 Jan 24;33(2):262-78.
40. Vinogradov SV. Nanogels in the race for drug delivery. Nanomedicine. 2010 Feb;5(2):165-8.
41. Chanchal DK, Alok S, Kumar M, Bijauliya RK, Rashi S, Gupta S. A Brief Review on Abelmoschus esculentus linn. okra. International Journal of Pharmaceutical Sciences and Research. 2018 Jan 1;9(1):58-66.
42. Singh S, Jain SK, Alok S, Chanchal D, Rashi S, Pradesh U. A review on Ficus religiosa-An important medicinal plant. Int J Life Sci Rev (IJLSR). 2016;2(1):1-1.
43. Dongray A, Irchhaiya R, Chanchal D, Chaudhary S. Phytochemical and pharmacological properties of Bauhinia acuminata. World journal of pharmaceutical research. 2016;5(1):531-46.
44. Bijauliya RK, Alok S, Kumar M, Chanchal DK, Yadav S. A comprehensive review on herbal cosmetics. International Journal of Pharmaceutical Sciences and Research. 2017 Dec 1;8(12):4930-49.
45. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H, Tahriri M, Tayebi L, Hamblin MR. Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta biomaterialia. 2019 Jul 1;92:1-8.
46. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angewandte Chemie International Edition. 2009 Jul 13;48(30):5418-29.
47. Navarro L, Theune LE, Calderon M. Effect of crosslinking density on thermoresponsive nanogels: A study on the size control and the kinetics release of biomacromolecules. European Polymer Journal. 2020 Feb 5;124:109478.
48. Cuggino JC, Blanco ER, Gugliotta LM, Igarzabal CI, Calderón M. Crossing biological barriers with nanogels to improve drug delivery performance. Journal of controlled release. 2019 Aug 10;307:221-46.
49. Altuntaş E, Özkan B, Güngör S, Özsoy Y. Biopolymer-based nanogel approach in drug delivery: basic concept and current developments. Pharmaceutics. 2023 Jun 2;15(6):1644.
50. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials. 2012 Feb 1;33(5):1607-17.
51. Bijauliya RK, Alok S, Chanchal DK, Kumar M. A comprehensive review on standardization of herbal drugs. Int. J. Pharm. Sci. Res. 2017 Sep 1;8(9):3663-77.
52. Bijauliya RK, Alok S, Chanchal DK, Sabharwal M, Yadav RD. An updated review of pharmacological studies on Azadirachta indica (neem). International Journal of Pharmaceutical Sciences and Research. 2018 Jul 1;9(7):2645-55.
53. Bijauliya RK, Alok S, Sabharwal M, Chanchal DK. Syzygium cumini (linn.)-an overview on morphology, cultivation, traditional uses and pharmacology. International Journal of Pharmaceutical Sciences and Research. 2018 Sep 1;9(9):3608-20.
54. Bijauliya RK, Alok S, Kumar M, Chanchal DK, Sabharwal M, Yadav RD. An update of pharmacological activity of Psidium guajava in the treatment of various diseases. International Journal of Pharmaceutical Sciences and Research. 2018 Mar 1;9(3):883-93.
55. Niladri M, Singh S, Porwal P, Chanchal DK, Macadangdang Jr RR, Patil PY. Formulation Development And Evaluation Of Terbinafine Using Quality By Design Approach. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO. 2021 Nov 7:2581-98.
56. Al-Hussainawy MK, Aljeboree AM, Jawad MA, Sheri FS, Alkaim AF. Preparation of Bentonite Clay/TiO_2 Nanocomposites Surface as Drug Carrier: In-vitro Release Study of Chloramphenicol Drug. International Journal of Drug Delivery Technology. 2023;13(3):990-994.
57. Chauhan NK, Malik A, Ratiyen PK. Solid Lipid Nanoparticles: Drug Delivery Systems for Enhancing the Bioavailability of Antihypertensives. International Journal of Drug Delivery Technology. 2023;13(3):1059-1064.
58. Gnana RPM, Devhare LD, Dharmamoorthy G, Khairnar MV, Prasidha R. Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):475-480.
59. Bukkawar A, Jain AK, Chatap VK. Formulation Development and Evaluation of Freeze-dried Aviptadil injection using Mannitol as Cryoprotectant. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):541-547.
60. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical research. 2008 Apr;25:781-91.
61. Tripathi NK, Shrivastava A. Scale up of biopharmaceuticals production. InNanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology 2018 Jan 1 (pp. 133-172). William Andrew Publishing.
62. Kaur M, Sudhakar K, Mishra V. Fabrication and biomedical potential of nanogels: An overview. International Journal of Polymeric Materials and Polymeric Biomaterials. 2019 Apr 13;68(6):287-96.
63. Vasowala T, Gharat S, Mhase M, Momin M. Advances in hydrogels based cutaneous drug delivery system for management of psoriasis. European Polymer Journal. 2023 Nov 28:112630.
64. Gungor S, Rezigue M. Nanocarriers mediated topical drug delivery for psoriasis treatment. Current Drug Metabolism. 2017 May 1;18(5):454-68.

65. Thakur S, Anjum MM, Jaiswal S, Gautam AK, Rajinikanth PS. Tazarotene-calcipotriol loaded Nanostructured lipid carrier enriched hydrogel: A novel dual drug synergistic approach towards Psoriasis management. Journal of Drug Delivery Science and Technology. 2023 Oct 1;88:104944.
66. Chandrashekhar BS, Anitha M, Ruparelia M, Vaidya P, Aamir R, Shah S, Thilak S, Aurangabadkar S, Pal S, Saraswat A, Sanmukhani JJ. Tretinoin nanogel 0.025% versus conventional gel 0.025% in patients with acne vulgaris: a randomized, active controlled, multicentre, parallel group, phase IV clinical trial. Journal of clinical and diagnostic research: JCDR. 2015 Jan;9(1):WC04.
67. Mazo AR, Allison-Logan S, Karimi F, Chan NJ, Qiu W, Duan W, O'Brien-Simpson NM, Qiao GG. Ring opening polymerization of α-amino acids: advances in synthesis, architecture and applications of polypeptides and their hybrids. Chemical society reviews. 2020;49(14):4737-834.
68. Kaur L, Jain SK, Singh K. Vitamin E TPGS based nanogel for the skin targeting of high molecular weight anti-fungal drug: development and in vitro and in vivo assessment. RSC advances. 2015;5(66):53671-86.
69. Bagde A, Patel K, Mondal A, Kutlehria S, Chowdhury N, Gebeyehu A, Patel N, Kumar N, Singh M. Combination of UVB absorbing titanium dioxide and quercetin nanogel for skin cancer chemoprevention. AAPS PharmSciTech. 2019 Aug;20:1-2.
70. Wu Y, Tao Q, Xie J, Lu L, Xie X, Zhang Y, Jin Y. Advances in nanogels for topical drug delivery in ocular diseases. Gels. 2023 Apr 2;9(4):292.
71. Nguyen DT, Nguyen TP, Nguyen NH, Nguyen KT, Nguyen TH, Ngan TT, Nhi TT, Le BH, Le Thi P, Tran NQ. Potential from synergistic effect of quercetin and paclitaxel co-encapsulated in the targeted folic–gelatin–pluronic P123 nanogels for chemotherapy. International Journal of Biological Macromolecules. 2023 Jul 15;243:125248.
72. Arora D, Rana S, Gupta GD, Chaudhary A, Singh B. Oral Mucosal Immunization Recent Advancement and Exploit Dendritic Cell Targeting. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):704-11.